Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans

Overview of attention for article published in Psychopharmacology, April 2003

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (72nd percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

patent: 17 patents

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 167 Dimensions

Readers on

mendeley: 56 Mendeley

Summary Patents Wikipedia Dimensions citations

So far, Altmetric has seen 1 Wikipedia article.

English

Eglumegad

Cited by user Boghog on 29 Sep 2013

Eglumegad (LY354740) is a research drug developed by Eli Lilly and Company, which is being investigated for its potential in the treatment of anxiety and drug addiction.

This page shows the most recent Wikipedia articles that mention this research output.

Click here to find out how to access more activity.